Takeda Pharmaceutical Net Income vs. Return On Asset
| TAK Stock | USD 13.33 0.04 0.30% |
Net Income | First Reported 2008-09-30 | Previous Quarter 95.2 B | Current Value 92 B | Quarterly Volatility 61.8 B |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.78 | 0.5125 |
|
|
For Takeda Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Takeda Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Takeda Pharmaceutical Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Takeda Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Takeda Pharmaceutical Co over time as well as its relative position and ranking within its peers.
Takeda |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.59 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Takeda Pharmaceutical Return On Asset vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Takeda Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Takeda Pharmaceutical value to that of its competitors to determine the firm's financial worth. Takeda Pharmaceutical Co is currently regarded as top stock in net income category among its peers. It is rated below average in return on asset category among its peers . The ratio of Net Income to Return On Asset for Takeda Pharmaceutical Co is about 5,182,266,187,050 . At this time, Takeda Pharmaceutical's Net Income is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Takeda Pharmaceutical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Takeda Return On Asset vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Takeda Pharmaceutical |
| = | 144.07 B |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Takeda Pharmaceutical |
| = | 0.0278 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Takeda Return On Asset Comparison
Takeda Pharmaceutical is currently under evaluation in return on asset category among its peers.
Takeda Pharmaceutical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Takeda Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Takeda Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Takeda Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Takeda Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 2.5 T | 2.6 T | |
| Operating Income | 214.1 B | 225 B | |
| Income Before Tax | 52.8 B | 50.2 B | |
| Total Other Income Expense Net | -161.3 B | -153.2 B | |
| Net Income | 144.1 B | 217.6 B | |
| Income Tax Expense | -91.4 B | -86.8 B | |
| Net Income From Continuing Ops | 144.2 B | 167.4 B | |
| Net Income Applicable To Common Shares | 364.6 B | 382.8 B | |
| Net Interest Income | -140.5 B | -147.5 B | |
| Interest Income | 11.3 B | 10.7 B | |
| Change To Netincome | 24.2 B | 25.4 B | |
| Net Income Per Share | 92.09 | 138.75 | |
| Income Quality | 4.44 | 4.67 | |
| Net Income Per E B T | 2.73 | 2.87 |
Takeda Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Takeda Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Takeda Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Takeda Pharmaceutical's important profitability drivers and their relationship over time.
Use Takeda Pharmaceutical in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Takeda Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Takeda Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Takeda Pharmaceutical Pair Trading
Takeda Pharmaceutical Co Pair Trading Analysis
The ability to find closely correlated positions to Takeda Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Takeda Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Takeda Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Takeda Pharmaceutical Co to buy it.
The correlation of Takeda Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Takeda Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Takeda Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Takeda Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Takeda Pharmaceutical position
In addition to having Takeda Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Energy Thematic Idea Now
Alternative Energy
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
To fully project Takeda Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Takeda Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Takeda Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.